Global Fondaparinux Sodium Market to Grow Considerably due to Rising Prevalence of Chronic Ailments

1. Welcome To Dataintelo Latest Reports Global Fondaparinux Sodium Market to Grow Considerably due to Rising Prevalence of Chronic Ailments The global fondaparinux sodium market is anticipated to rise at a considerable CAGR during the forecast period. Fondaparinux sodium is used to prevent venous thromboembolic events in patients with orthopedic surgeries such as hip fracture and knee replacement. Fondaparinux sodium is known as axrixtra and is used for surgical purpose. The fondaparinux sodium market is majorly driven by the rise in orthopedic surgeries and collaborations among key players for strengthening medical alliances. The collaboration is intended to secure a prominent position to gain licensed molecule. Additionally, the market is projected to expand due to factors such as intensive R&D to enable good health among patients and reduce overhead costs of medicines. Subsequently, rise in geriatric population and chronic ailments and treatments for the same is likely to boost market growth. Rising incidences of diabetes and age-related diseases needing timely attention, propels the growth of the fondaparinux sodium market. However, complex manufacturing procedures, significant costs of treatment, and rising incidences of side effects of the treatment in emerging economies are expected to restrain market growth during the forecast period. Based on products, the fondaparinux sodium market has been bifurcated into generic drugs and branded drugs. In terms of end-users, the market has been divided into hospitals, home care settings, clinics, research centers, and diagnostic centers. On the basis of applications, the market has been classified as abdominal surgery, knee replacement, cardiovascular, and orthopedics. Based on regions, the global fondaparinux sodium market has been segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is estimated to expand at a high CAGR during the forecast period owing to favorable medical infrastructure and positive reimbursement policies. Moreover, factors such as rise in use of generic drugs and increase in geriatric population fuels the market in the region. The marekt in Asia Pacific is projected to expand at a considerable pace due to the rise in patient pool and availability of relevant diagnostics and medical help. Key players in the global fondaparinux sodium market include Pfizer Inc, Bayer Healthcare AG, GlaxoSmithkline Plc, Sanofi S.A, Boehringer Ingelheim, Apotex, Aspen Holdings, Abbott India Limited, Bristol-Myers Squibb Company, WisMed Pharmaceuticals, and Kaifeng Pharmaceutical. Discover More at: https://dataintelo.com/